By Drug Target Review2025-06-03T08:30:27
Researchers at the University of Michigan have engineered a herpes virus protein to enhance T cell survival and function, offering a new strategy to strengthen cancer immunotherapy.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-30T09:54:00Z
2023-03-20T13:41:33
Sponsored by Bio-Techne
2023-03-07T10:55:58
Sponsored by Agilent
2023-01-06T16:37:30
Sponsored by Catalent
2025-10-22T14:00:00
Sponsored by Wuxi Biologics
2025-07-30T08:00:00
Sponsored by Wuxi Biologics
2025-06-11T14:00:00
Sponsored by Eurofins Discovery
Site powered by Webvision Cloud